risperidone has been researched along with Disease Exacerbation in 22 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 39-year-old man with schizophrenia developed severe catatonia, hyperthermia, muscle rigidity, tachycardia, leukocytosis, and elevated muscle enzyme levels while receiving zotepine therapy." | 7.73 | Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. ( Chen, CC; Tsai, JH; Yang, MJ; Yang, P; Yen, JY, 2005) |
| "A 39-year-old man with schizophrenia developed severe catatonia, hyperthermia, muscle rigidity, tachycardia, leukocytosis, and elevated muscle enzyme levels while receiving zotepine therapy." | 3.73 | Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. ( Chen, CC; Tsai, JH; Yang, MJ; Yang, P; Yen, JY, 2005) |
| "CATIE-AD included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior who were randomly assigned to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo." | 2.76 | Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. ( Dagerman, KS; Hsiao, JK; Keefe, RS; Lebowitz, BD; Lyketsos, CG; Mack, WJ; Sano, M; Schneider, LS; Stroup, TS; Sultzer, DL; Tariot, PN; Vigen, CL; Zheng, L, 2011) |
| "Hallucinations and psychosis are common in patients with Parkinson's disease (PD), with reported prevalences of up to 48% and 80%, respectively." | 2.46 | Management of hallucinations and psychosis in Parkinson's disease. ( Eng, ML; Welty, TE, 2010) |
| "Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed." | 2.41 | Guidelines for managing Alzheimer's disease: Part II. Treatment. ( Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B, 2002) |
| "The increasing recognition of Tourette's syndrome is probably responsible for the broadening range of symptom severities seen in clinic patients." | 2.39 | Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. ( Peterson, BS, 1996) |
| "UHDRS (Unified Huntington's Disease Rating Scale) motor scores were obtained from medical records as an index of disease progression." | 1.42 | Examining Huntington's disease patient and informant concordance on frontally mediated behaviors. ( Cimino, CR; Hergert, DC; Sanchez-Ramos, J, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Rojo-Moreno, J | 1 |
| Rojo-Valdemoro, C | 1 |
| Santolaya-Ochando, F | 1 |
| Carlone, D | 1 |
| Delva, N | 1 |
| Dal Mas, C | 1 |
| Nani, JV | 1 |
| Noto, C | 1 |
| Yonamine, CM | 1 |
| da Cunha, GR | 1 |
| Mansur, RB | 1 |
| Ota, VK | 1 |
| Belangero, SI | 1 |
| Cordeiro, Q | 1 |
| Kapczinski, F | 1 |
| Brietzke, E | 1 |
| Bressan, RA | 1 |
| Gadelha, A | 1 |
| Hayashi, MAF | 1 |
| Molina, V | 1 |
| Taboada, D | 1 |
| Aragüés, M | 1 |
| Hernández, JA | 1 |
| Sanz-Fuentenebro, J | 1 |
| Kazdal, H | 1 |
| Kanat, A | 1 |
| Sen, A | 1 |
| Kirbas, S | 1 |
| Ardic, G | 1 |
| Tufekci, A | 1 |
| Ersoz, T | 1 |
| Hergert, DC | 1 |
| Sanchez-Ramos, J | 1 |
| Cimino, CR | 1 |
| Takahashi, T | 1 |
| Wood, SJ | 1 |
| Yung, AR | 2 |
| Soulsby, B | 1 |
| McGorry, PD | 3 |
| Suzuki, M | 1 |
| Kawasaki, Y | 1 |
| Phillips, LJ | 2 |
| Velakoulis, D | 1 |
| Pantelis, C | 1 |
| Chittiprol, S | 1 |
| Venkatasubramanian, G | 1 |
| Neelakantachar, N | 1 |
| Reddy, NA | 1 |
| Shetty, KT | 1 |
| Gangadhar, BN | 1 |
| Eng, ML | 1 |
| Welty, TE | 1 |
| Vigen, CL | 1 |
| Mack, WJ | 1 |
| Keefe, RS | 1 |
| Sano, M | 1 |
| Sultzer, DL | 1 |
| Stroup, TS | 1 |
| Dagerman, KS | 1 |
| Hsiao, JK | 1 |
| Lebowitz, BD | 1 |
| Lyketsos, CG | 1 |
| Tariot, PN | 1 |
| Zheng, L | 1 |
| Schneider, LS | 1 |
| Schennach, R | 1 |
| Riesbeck, M | 1 |
| Mayr, A | 1 |
| Seemüller, F | 1 |
| Maier, W | 1 |
| Klingberg, S | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Gastpar, M | 1 |
| Schmitt, A | 1 |
| Sauer, H | 1 |
| Schneider, F | 1 |
| Jäger, M | 1 |
| Wölwer, W | 1 |
| Gaebel, W | 1 |
| Möller, HJ | 1 |
| Riedel, M | 1 |
| Yuen, HP | 1 |
| Francey, S | 1 |
| Cosgrave, EM | 1 |
| Germano, D | 1 |
| Bravin, J | 1 |
| McDonald, T | 1 |
| Blair, A | 1 |
| Adlard, S | 1 |
| Jackson, H | 1 |
| Kafantaris, V | 1 |
| Coletti, DJ | 1 |
| Dicker, R | 1 |
| Padula, G | 1 |
| Pleak, RR | 1 |
| Alvir, JM | 1 |
| Lambert, M | 1 |
| Conus, P | 1 |
| Lubman, DI | 1 |
| Wade, D | 1 |
| Yuen, H | 1 |
| Moritz, S | 1 |
| Naber, D | 1 |
| Schimmelmann, BG | 1 |
| Tsai, JH | 1 |
| Yang, P | 1 |
| Yen, JY | 1 |
| Chen, CC | 1 |
| Yang, MJ | 1 |
| Wu, PL | 1 |
| Lane, HY | 1 |
| Su, KP | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Peterson, BS | 1 |
| Meco, G | 1 |
| Alessandri, A | 1 |
| Giustini, P | 1 |
| Bonifati, V | 1 |
| Waddington, JL | 1 |
| Scully, PJ | 1 |
| O'Callaghan, E | 1 |
| Volavka, J | 1 |
| Citrome, L | 1 |
| Cummings, JL | 1 |
| Frank, JC | 1 |
| Cherry, D | 1 |
| Kohatsu, ND | 1 |
| Kemp, B | 1 |
| Hewett, L | 1 |
| Mittman, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Real-world Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-risk for Psychosis: Study Protocol for a Prospective Observational Study (SHARP-2)[NCT04010864] | 600 participants (Anticipated) | Observational [Patient Registry] | 2019-03-29 | Recruiting | |||
| CLUES (Cognition for Learning and for Understanding Everyday Social Situations): An Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis[NCT02459210] | 58 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for risperidone and Disease Exacerbation
| Article | Year |
|---|---|
Management of hallucinations and psychosis in Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Comorbidity; Delusions; Demen | 2010 |
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Child; Clozapine; Disease Progression; Diseas | 1996 |
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Disease Progressio | 1999 |
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; D | 2002 |
6 trials available for risperidone and Disease Exacerbation
| Article | Year |
|---|---|
Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Bipolar Disorder; Cognitive Behavioral Therapy; Co | 2009 |
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzod | 2011 |
Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?
Topics: Adult; Antipsychotic Agents; Disease Progression; Double-Blind Method; Female; Haloperidol; Humans; | 2013 |
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study.
Topics: Acute Disease; Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Bri | 2004 |
Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study.
Topics: Aged; Antipsychotic Agents; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; | 1997 |
12 other studies available for risperidone and Disease Exacerbation
| Article | Year |
|---|---|
Royal Eschizophilia. Genealogical delusion or Mignon delusion as a pathoplastic realization.
Topics: Age Factors; Antipsychotic Agents; Carbamazepine; Delusions; Disease Progression; Fellowships and Sc | 2019 |
Long-acting injectable antipsychotics: choosing the right dose.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Disease Progression; Drug Substitution; Humans; I | 2020 |
Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Biomarkers; Carrier Proteins; Cohort Studies; Disease Progr | 2019 |
Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Disease Progression; Female; Follow-Up | 2014 |
A novel clinical observation in neuroleptic malignant-like syndrome: first demonstration of early progression of hydrocephalus.
Topics: Aged; Antipsychotic Agents; Depressive Disorder, Major; Disease Progression; Fatal Outcome; Female; | 2015 |
Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
Topics: Adult; Aged; Antipsychotic Agents; Awareness; Cognition Disorders; Disease Progression; Female; Fron | 2015 |
Longitudinal study of beta2-microglobulin abnormalities in schizophrenia.
Topics: Adult; Antipsychotic Agents; beta 2-Microglobulin; Disease Progression; Female; Follow-Up Studies; H | 2009 |
The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Australia; Benzodiazepines; Cohort Studies; Disease Progression; Female | 2005 |
Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Blood Chemical Analysis; Catatonia; Dibenzothiepins; Disease Progression; Feve | 2005 |
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Disease Progression; Humans | 2006 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
The new antipsychotics, and their potential for early intervention in schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Disease Progression; Dopamine Antagonists; Humans; Risperidone; Sch | 1997 |